🇺🇸 FDA
Patent

US 11497736

Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease

granted A61KA61K31/4245A61K9/0053

Quick answer

US patent 11497736 (Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease) held by PTC THERAPEUTICS, INC. expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/4245, A61K9/0053, A61K9/145, A61P